Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884601 | 0.82 | PIK3CD (0.47) | PIK3CDPIK3CGDHODH | |
| SCHEMBL4184462 | 0.79 | PIK3CD (0.47) | PIK3CDPIK3CG | |
| SCHEMBL1887094 | 0.75 | PIK3CD (0.45) | PIK3CD | |
| SCHEMBL12004063 | 0.72 | TRPA1 (0.40) | PIK3CD | |
| SCHEMBL1877699 | 0.71 | PIK3CD (0.45) | PIK3CD | |
| SCHEMBL17928702 | 0.70 | PIK3CD (0.45) | PIK3CDPIK3CG | |
| SCHEMBL4178472 | 0.69 | PIK3CD (0.49) | PIK3CD | |
| SCHEMBL10250951 | 0.69 | PIK3CD (0.47) | PIK3CDPIK3CG | |
| SCHEMBL1879939 | 0.69 | PIK3CD (0.45) | PIK3CDALDH1A1 | |
| SCHEMBL1888178 | 0.69 | PIK3CD (0.45) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | PIK3CD 8/4885PIK3CG 9/4885EGFR 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.